IDD Therapeutics

Company Overview

Snapshot

Founded in January 2010 by Anwar Rayan, IDD Therapeutics operates with 1–10 employees. The company has secured funding across one round from the Office of the Chief Scientist. A key development for the company was its operation within the New Generation Technology (NGT) incubator, supported by the Israeli Office of the Chief Scientist and private capital.

Business overview

IDD Therapeutics Ltd develops drugs for cancer therapy, focusing on enhancing the safety and efficacy of existing cancer treatments and protocols. The company leverages its proprietary Intelligent Learning Engine (ILE) to design targeted small-molecule New Therapeutic Entities (NTEs) for cancer therapy. Its product pipeline includes IDD-1040, a neuro-protective antioxidant moiety, and early preclinical drug candidates IDD-1010 and IDD-2010. IDD Therapeutics operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the pharmaceutical industry.

Company Intelligence Q&A

What is IDD Therapeutics' primary focus?

IDD Therapeutics Ltd develops drugs for cancer therapy, with a primary focus on improving the safety and efficacy of existing cancer treatments and protocols.

What technology does IDD Therapeutics utilize for drug discovery?

The company uses its proprietary Intelligent Learning Engine (ILE) to help researchers design targeted small-molecule New Therapeutic Entities (NTEs) for cancer therapy.

What are some of IDD Therapeutics' drug candidates?

IDD Therapeutics is developing IDD-1040, a targeted, multifunctional Mode of Action (MoA) NTE. Additional drug candidates, IDD-1010 and IDD-2010, are currently at the early preclinical stage.

Where is IDD Therapeutics located?

IDD Therapeutics has an address in Nazareth, Israel.

What is the status of IDD Therapeutics?

IDD Therapeutics is currently non-active as of January 2014.